Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first and is committed to empowering healthcare providers and patients with the goal of improved health outcomes. Primarily focused on dermatologic cancers and gastroenterological disease, Castle’s innovative tests are designed to help answer critical clinical questions and address treatment plan challenges facing clinicians to better inform patient care decisions. Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Using its expertise in advanced technologies, such as genomics, spatialomics, data analytics and artificial intelligence, Castle digs deep into treatment pathways to develop personalized, clinically actionable tests that can improve, and potentially transform, the management of diseases and patient outcomes. | At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
